Michael Grunkin Ph.D. - CEO
Amanda Lowe - Senior Vice President, Americas
Read more about the management here
Traditional microscopic view of a tissue stained with Ki-67
Visiopharm's Image analysis overlay for the microscopic view of a tissue stained with Ki-67. Detection of positive and negative nuclei, for quantification of Ki-67.
Ki-67 Breast Cancer APP
The Ki-67 protein is associated with cellular proliferation, and the protein is present in the nucleus of all cells that are in the active phase of the cell cycle, but absent in resting cells. The cell proliferation rate can be assessed by Ki-67-immunohistochemical (IHC) staining, and this can be correlated to the tumor grade and the clinical course.
This protocol can be used to assess tumors by determining the Ki-67 positivity. The protocol provides the number of positive nuclei as well as the total number of nuclei.
Hot Spot APP
One of the more recent approaches to Ki-67 scoring is the hot spot scoring method, which has been implemented to multiple scoring guidelines. However, this scoring method lacks standardization and is often found to be subjective and prone to both intra- and inter-observer variability. Visiopharm’s Hot spot APP provides a standardized and objective method for scoring in hot spots.
Traditional p63 and CK7/19 stained tissue sample.
Visiopharm's image analysis overlay. Detection of invasive and non-invasive tumor.
Invasive Tumor Detection (PDS) APP
Whether a cancer is invasive or non-invasive will determine the treatment choices and how a patient might respond to the treatment he or she receives. Most breast cancers are invasive, but in some cases both invasive and non-invasive cancer can be seen in the same specimen. In these cases, it is necessary with a tool that can distinguish between the invasive tumor components and the non-invasive tumor components so that the biomarker expression, e.g. Ki-67 or ER, within the invasive cancer, can be accurately assessed. The “Invasive Tumor Detection (PDS)” APP provide means for distinguishing between invasive tumor and non-invasive.
PD-L1 Cell Line APP
The availability of genetically defined reference materials, offers an industry standard for development and quality control of IHC assays, directly, thereby improving the accuracy and reproducibility. Using engineered cell lines as quality control material to assess the performance of IHC assays eliminates the variability associated with patient-derived reference standards. This APP can be used for quality control of PD-L1 strong positive, intermediate positive, weak positive and negative cell line material.